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Advances in biotechnology have led to human genome editing and 
to progress in artificial intelligence (AI), fuelling the Fourth Industrial 
Revolution. With these advances and their gaining momentum come 
promises for wellbeing at a level not previously imagined. Undoubtedly, 
along with these promises, ethical, legal and social considerations 
surface, and valid concerns that the law and ethics are lagging behind 
justifiably emerge.
Genome editing involves precise additions, deletions and alterations 
to the genome. Basic science research on genome editing is already 
underway in laboratories globally. Clinical applications involving 
somatic (non-reproductive) cells are in the early stages of development, 
and there is huge potential for the use of this technology in germline 
(reproductive) cells.[1] Pillay and Thaldar,[2] in this issue, discuss the legal 
situation, and underscore the point that gene-editing technologies 
such as the most recent CRISPR system pose challenges to South 
African (SA) biotechnology law. They highlight the ambiguities within 
section 57 of the National Health Act (NHA)[3] with regard to the broad 
definition of reproductive cloning, which possibly includes germline 
genome editing. Reproductive cloning, in terms of the NHA, is banned, 
and depending on how its definition is interpreted, the ban could 
extend to include germline genome editing. 
Ethical considerations arise across the spectrum with regard to 
genome editing – at the levels of basic science research, somatic-cell 
editing and germline editing. Basic science research is undeniably 
critical to advancing biomedical science. The same applies to basic 
science research involving genome editing. Our understanding of the 
molecular processes that control disease development and progression 
is advanced by genome-editing research using somatic cells. The 
potential for this to enable the development of better interventions 
for people who are affected by these diseases is immense. Genome-
editing research of germline cells will assist with the understanding of 
human development and fertility, and hence could support progress 
in fertility treatments, regenerative therapies and other related medical 
applications.[1] Gene therapy, where genetic changes are made to 
somatic cells, is an established modality of treatment, and genome 
editing for somatic applications would not be dissimilar. Somatic 
genome editing could be performed either outside, or directly inside, 
the body. While the latter could pose technical challenges, in that 
the gene-editing tools may not find their target genes efficiently, 
or may inadvertently affect germline cells, clinical trials using this 
technology for some diseases have already been embarked upon 
in some countries. Prenatal and preimplantation genetic diagnosis 
to avert disease transmission has been used for some time already. 
However, these technologies do not work in some cases, and where 
they do work, could result in discarding affected embryos, or in 
selective abortion, giving rise to beginning-of-life age-old debates. 
Germline genome editing could provide some families with the most 
appropriate option for averting disease transmission, and the resulting 
genetic changes would then be passed down the generations. This 
shift away from purely individual-level effects is viewed as contentious 
by some. Social and ethical concerns, including those involving the accep-
tance of children with disabilities, the risk of inheriting off-target 
genome effects, equitable access and slippery-slope cautions in the 
contexts of enhancement and eugenics, are being debated. Genome 
editing for enhancement purposes would involve both somatic and 
germline processes. Enriching traits and capacities beyond levels 
considered adequate for health is a realistic possibility, and invokes 
considerations of fairness, social norms and the need for both public 
debate and regulation.[1,4] 
Following broad consultation, the US National Academy of Sciences 
recommended that heritable genome-editing clinical trials be 
permitted within a framework of due care and responsible science, 
which entails that the following criteria must be satisfied:[1] 
• an absence of reasonable alternatives;
• restriction to preventing a serious disease or condition;
• restriction to editing genes that have been convincingly demonstrated 
to cause or to strongly predispose to the disease or condition;
• restriction to converting such genes to versions that are prevalent in 
the population and are known to be associated with ordinary health, 
with little or no evidence of adverse effects;
• availability of credible preclinical and/or clinical data on risks and 
potential health benefits of the procedures;
• ongoing, rigorous oversight during clinical trials of the effects of the 
procedure on the health and safety of the research participants; 
• comprehensive plans for long-term, multigenerational follow-up 
that still respects personal autonomy;
• maximum transparency, consistent with patient privacy;
• continued reassessment of both health and societal benefits and 
risks, with broad ongoing participation and input by the public; and
• reliable oversight mechanisms to prevent extension to uses other 
than preventing a serious disease or condition. 
Seven principles for the governance of human genome editing are 
proposed by the Academy: promoting wellbeing, transparency, 
due care, responsible science, respect for persons, fairness and 
transnational co-operation.[1] The Nuffield Council on the ethical 
acceptability of genome editing in the context of reproduction, 
has proposed two principles to be satisfied. Firstly, the intention of 
the intervention is to secure the welfare of the individual born as a 
result of such technology. Moreover, the intervention must also be 
consistent with the welfare of such a person. Secondly, principles of 
social justice and solidarity are upheld, and the intervention should 
not result in an intensifying of social divides or marginalising of 
disadvantaged groups in society.[4] 
Mahomed,[5] in her article in this issue on artificial intelligence (AI) and 
the Fourth Industrial Revolution in healthcare, highlights the promise 
of these advances, even in the context of resource scarcity. She briefly 
addresses the impact and importance of AI in the healthcare setting, 
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and discusses some concerns with regard to the ethical, social and 
legal challenges that could arise with its implementation in the African 
context. Just as gene editing, under the umbrella of gene therapy, is 
not new, AI, too, is not a new notion, and has been recognised in the 
field of medicine since as far back as the 1970s. What is new is the rapid 
growth of AI, resulting in the powerful push behind the Fourth Industrial 
Revolution. Ethical considerations include those around eroding the 
human element in healthcare, data security and bias, and quality control 
and standards.[5] The ethical principles recommended by the National 
Academy and the Nuffield Council, albeit for genome editing, will 
apply in the context of AI as well. In addition, some laws may require 
amendments, and there may be a need for the development of new laws 
to address possible legal hiatuses in this context. 
SA is internationally renowned for its expertise in research. 
In addition, it has, over the past few decades, developed robust 
international collaborations in the context of health research. With 
these advances in science and technology gaining momentum, 
it is inevitable that both local and international institutions and 
laboratories will proceed to utilise our local expertise. Academic 
discussion and debate, coupled with public engagement, are 
necessary so that ethical and social considerations can be used 
to inform the updating of our laws. This could allow for suitable 
safeguards that facilitate ethical research and clinical management, 
rather than blindly obstruct these advances, to the detriment of 
our wellbeing. In addition, because laws differ between national 
jurisdictions, there needs to be mutual respect for differing national 
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